Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O/AZD2281) in combination with carboplatin (C) in ovarian cancer (OvCa) patients with BRCA1/2 mutations (OvCaMUT+) and high grade serous OvCa (HGSOC) with low genetic risk (NCT00647062)
Year: 2013
Type: article
Study design: Clinical Trial
Source: Gynecologic Oncology
Authors: J. Lee, J. Hays, A. Noonan, C. Annunziata, L. Minasian, J. Zujewski, N. Houston, J. Hearn, M. Yu, E. Kohn
Institutions: National Cancer Institute, National Institutes of Health
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W1967039776